Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

CORONA Remedies IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2004 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size 485.53 Cr
Profile
Price Range 1008  to  1062 per share
Profile
Min Investment ₹1062
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

We are an India-focused branded pharmaceutical formulation company engaged in developing, manufacturingand marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeuticareas. According to the Industry Report, we are the second fastest growing company among the top 30 companiesin the Indian Pharmaceutical Market (“IPM”) in terms of domestic sales between MAT December 2021 and MAT December 2024. During this period, our domestic sales grew at a CAGR of 19.90%, compared to the IPM whichgrew at a CAGR of 8.79%, displaying a growth of more than 2.25 times the IPM’s growth (Source: IndustryReport). This has been driven by our growth in volume (at an average of 9.58% over the above period, comparedto the IPM’s growth of 1.65%), and new product launches (at an average of 3.91% over the above period,compared to the IPM’s growth of 1.68%) Read More

Basic Info

Face Value 10 per share

Price 1008  to  1062 per share

P/E (x) 43.5

Sales( Cr.) 1196

PAT( Cr.) 149

EPS 24.4

Draft Prospectus

Exchange BSE-NSE

Promoter

Company Promoters

Kirtikumar Laxmidas Mehta Niravkumar Kirtikumar Mehta Ankur Kirtikumar Mehta

Pre Issue Share Holding 72.5%

Post Issue Share Holding 68.99%

Listing Details:

Listing Price: 1452

Listing Gain: 26.86%

Current Price: 1676.7

Gain On Issue: 1676.7 | 0%

GMP: 342.5

GMP %: 32.3 %

IPO Tentative Timetable

Opening Date Dec 08, 2025
Closing Date Dec 10, 2025
Allotment Dec 11, 2025
Refund Dec 12, 2025
Delivery of Shares Dec 12, 2025
Listing Date Dec 15, 2025

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 14 14,868
Retail (Max) 13 182 193,284
S-HNI (Min) 14 196 208,152
S-HNI (Max) 67 938 996,156
B-HNI (Min) 68 952 1,011,024

Objective of the Issue

Issue

Category Nos Bid Bid (x)
QIB 1288732 358939448 278.5x
NII 966549 201897066 208.9x
Retail 2255281 64802038 28.7x
EMP 61320 902888 14.7x
Total 4571882 626541440 137x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

CORONA Remedies Profit & Loss

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 884 1014 1196
Other Income 7 6 6
Total Income 891 1021 1202
Total Expenditure 756 860 956
Operating Profit 135 161 246
Interest 4 14 11
Depreciation 20 28 37
Exceptional Income / Expenses 0 0 0
Profit Before Tax 111 118 199
Provision for Tax 26 28 49
Profit After Tax 85 91 149
Adjustments 0 0 0
Profit After Adjustments 85 91 149
Adjusted Earnings Per Share 13.9 14.8 24.4

CORONA Remedies Balance Sheet

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 409 480 606
Minority's Interest 0 0 0
Borrowings 0 67 16
Other Non-Current Liabilities 45 59 68
Total Current Liabilities 209 269 327
Total Liabilities 663 875 1017
Fixed Assets 185 384 370
Other Non-Current Assets 115 157 221
Total Current Assets 363 335 426
Total Assets 663 875 1017

CORONA Remedies Cash Flow

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 7 14 3
Cash Flow from Operating Activities 103 157 190
Cash Flow from Investing Activities -50 -267 -84
Cash Flow from Financing Activities -45 99 -107
Net Cash Inflow / Outflow 8 -11 0
Closing Cash & Cash Equivalent 14 3 3

CORONA Remedies Ratios

# Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 13.89 14.8 24.43
CEPS(Rs) 17.17 19.42 30.51
DPS(Rs) 2.77 3.7 7.31
Book NAV/Share(Rs) 66.8 78.55 99.14
Core EBITDA Margin(%) 14.25 14.92 19.71
EBIT Margin(%) 12.82 12.82 17.17
Pre Tax Margin(%) 12.35 11.42 16.3
PAT Margin (%) 9.46 8.73 12.27
Cash Profit Margin (%) 11.69 11.45 15.32
ROA(%) 12.82 11.77 15.79
ROE(%) 20.79 20.36 27.5
ROCE(%) 28.03 25.93 32.59
Receivable days 35.35 32.89 32.7
Inventory Days 42.83 35.85 34.14
Payable days 163.28 167.89 198.94
PER(x) 0 0 0
Price/Book(x) 0 0 0
Dividend Yield(%) 0 0 0
EV/Net Sales(x) -0.01 0.12 0.05
EV/Core EBITDA(x) -0.1 0.78 0.22
Net Sales Growth(%) 0 14.75 17.93
EBIT Growth(%) 0 15.43 57.34
PAT Growth(%) 0 6.56 65.12
EPS Growth(%) 0 6.56 65.12
Debt/Equity(x) 0.01 0.28 0.1
Current Ratio(x) 1.74 1.24 1.3
Quick Ratio(x) 1.23 0.88 0.91
Interest Cover(x) 26.98 9.21 19.72
Total Debt/Mcap(x) 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 18% 0% 0% 0%
Operating Profit CAGR 53% 0% 0% 0%
PAT CAGR 64% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 28% 23% 23% 23%
ROCE Average 33% 29% 29% 29%

Company Contact Information

CORONA Remedies Ltd.

Chetna Prabhatkumar Dharajiya

+91 79 4023 3000

complianceofficer@coronaremedies.com

C – Mondeal Business Park Near Gurudwara, S. G. Highway Thaltej

IPO Lead Manager(s)

CORONA Remedies Ltd.

JM Financial Ltd.

IIFL Capital Services Ltd.

Kotak Mahindra Capital Co Ltd

Registrar Info

CORONA Remedies Ltd.

Bigshare Services Pvt Ltd

Office No S6-2, 6th Floor, Pinnacle Business Park,ext to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai - 400093 (old address - Bharat Tin Works building, 1st floor, Opp. Vasant Oasis, Andheri East Mumbai - 400 059 Tel: + 91 21 626 38200 Fax:

91-022-62638200

91-022-62638299

Investor@bigshareonline.com

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!